Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...
On August 7, 2025, Celltrion announced that it obtained FDA approval expanding the indication of the intravenous (IV) formulation of AVTOZMA (tocilizumab-anoh) to include treatment of cytokine release ...
Although the clinical data supporting the combination of teclistamab and daratumumab are exceptional, Luciano Costa, MD, PhD, ...
Talquetamab is a G protein–coupled receptor class C group 5 member D T-cell–engaging antibody, approved for relapsed/refractory multiple myeloma (RRMM). In the MonumenTAL-1 clinical trial, cytokine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results